<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Brief Overview of ART
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/brief-overview-art" data-history-node-id="2559" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Overview of Antiretroviral Therapy – Joseph Quintana
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
        </p>
        <table class="GridTable46" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Fixed Dose Combination regimens</td>
      <td>Fixed Dose Combination regimens</td>
      <td>Renal Dose Adj.</td>
      <td>Specific Considerations</td>
    </tr>
    <tr>
      <td>Biktarvy®</td>
      <td>Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide)</td>
      <td>d/c if CrCl &lt; 30; ok w/HD</td>
      <td>↑ Metformin levels Contraindicated w/: rifampin, dofetilide, rifabutin Avoid close admin. w/: laxatives, sucralfate, iron, calcium</td>
    </tr>
    <tr>
      <td>Triumeq®</td>
      <td>Abacavir/ Dolutegravir/ Lamivudine</td>
      <td>Dose adj individual components &lt;50 mg/min</td>
      <td>Dolutegravir can ↑ metformin &amp; dofetilide levels; dose adj needed w/rifampin use Same absorption issues with polyvalent cation administration (as below with bictegravir) also apply to dolutegravir</td>
    </tr>
    <tr>
      <td>Genvoya®</td>
      <td>Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir (Alafenamide)</td>
      <td>d/c if CrCl &lt; 30; ok in HD</td>
      <td>Many DDI with Genvoya (and other regimens with pharmacologic booster [cobicistat] due to CYP 3A4 inhibition</td>
    </tr>
  </tbody>
</table>
        </table>
        <p style="margin-bottom:1px">
        </p>
        <p style="margin-bottom:1px">
        </p>
        <table class="TableGrid9" style="width:99.68%; border-collapse:collapse; border:none" width="99%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Nuceloside RTI</td>
      <td>Dose adj</td>
      <td>Specific SE</td>
      <td>Major DDI</td>
      <td>Special Points</td>
    </tr>
    <tr>
      <td>Abacavir (ABC)</td>
      <td>Hepatic dysfunction</td>
      <td>↑ LDL/TG ↑ risk MI</td>
      <td>Tenofovir (df)</td>
      <td>Requires testing for HLA B5701; Avoid if previous hyper-sensitivity</td>
    </tr>
    <tr>
      <td>Emtricitabine (FTC)</td>
      <td>Renal (adj by CrCl)</td>
      <td>Rash, Insomnia, Rhabdomyolysis, Hyperpigmentation in palms/soles</td>
      <td>Lamivudine</td>
      <td>Active against HBV</td>
    </tr>
    <tr>
      <td>Lamivudine (3TC)</td>
      <td>Renal (adj by CrCl)</td>
      <td>Nausea, HA, peripheral neuropathy, neutropenia, rash</td>
      <td>Emtritabine</td>
      <td>Active against HBV</td>
    </tr>
    <tr>
      <td>Tenofovir Alafenamide (TAF)</td>
      <td>D/c for CrCl &lt; 15</td>
      <td>↑ lipids in TAF vs TDF</td>
      <td>AED’s may $ levels</td>
      <td>Tx of choice for HBV; ↑ lipids</td>
    </tr>
    <tr>
      <td>Tenofovir Disoproxil (TDF)</td>
      <td>Renal (adj by CrCl)</td>
      <td>N/V, # LFT, asymptomatic # CK</td>
      <td>--</td>
      <td>Active against HBV</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="background:white">
               <span style="font-family:Palatino">
                <span style="color:black">
                 NRTI Additional Information
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li style="list-style-type:none">
          <ul>
           <li style="list-style-type:none">
            <ul>
             <li style="list-style-type:none">
              <ul>
               <li style="list-style-type:none">
                <ul>
                 <li style="list-style-type:none">
                 </li>
                </ul>
               </li>
              </ul>
             </li>
            </ul>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Tenofovir
                 </span>
                </span>
               </span>
              </span>
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  alone is indicated for HBV, in which case you should be mindful of renal clearance when dosing. In HIV, it is only indicated in combination with emtricitabine and fixed-dose combination formulations, in which it is contraindicated if CrCl<30
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Class-wide Side Effect: Lactic acidosis, steatosis and lipoatrophy
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Resistance: M184V confers high resistance to emtricitabine and lamivudine, mid-level resistance to abacavir
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <p>
       </p>
       <p>
       </p>
       <table class="GridTable46" style="margin-left:-1px; border-collapse:collapse; border:none" width="99%">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Integrase Inhibitor</td>
      <td>Dose Adj.</td>
      <td>Specific SE</td>
      <td>Major DDI</td>
      <td>Special Points</td>
    </tr>
    <tr>
      <td>Raltegravir (RAL)</td>
      <td>--</td>
      <td>--</td>
      <td>Rifampin, AED’s</td>
      <td>--</td>
    </tr>
    <tr>
      <td>Dolutegravir (DTG)</td>
      <td>*see special points*</td>
      <td>Hyperglycemia Weight gain</td>
      <td>Rifampin, Efavirenz ↑metformin lvls</td>
      <td>Avoid close admin w/ laxatives, sucralfate,  iron, calcium May ↑Cr, w/o effect on renal fxn</td>
    </tr>
  </tbody>
</table>
       </table>
       <p style="margin-bottom:1px">
       </p>
       <p style="margin-bottom:1px">
       </p>
       <table class="ListTable46" style="margin-left:-1px; border-collapse:collapse; border:none" width="99%">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NNRTIs</td>
      <td>Hepatic Adj</td>
      <td>Specific SE</td>
      <td>Major DDI</td>
      <td>Special Points</td>
    </tr>
    <tr>
      <td>Efavirenz</td>
      <td>D/c if Child Pugh B/C</td>
      <td>Psychosis, vivid dreams, SI, mania, seizures; ↑ Lipids &amp; glucose</td>
      <td>Plavix, Azole, antifungals, some statins * clarithromycin, Buprenorphine</td>
      <td>Give before meals; d/c if rash develops</td>
    </tr>
    <tr>
      <td>Etravirine (ETR)</td>
      <td>NaN</td>
      <td>Hypersensitivity  ↑ Lipids &amp; glucose</td>
      <td>Plavix, clarithromycin</td>
      <td>NaN</td>
    </tr>
    <tr>
      <td>Nevirapine (NVP)</td>
      <td>D/c if Child Pugh B/C</td>
      <td>Steven Johnson Syndrome</td>
      <td>Azoles, OCP’s, statins, clarithro-mycin</td>
      <td>Don’t start if CD4 &gt;250 in women, CD4 &gt;400 in men; Don’t admin w/antacids</td>
    </tr>
    <tr>
      <td>Rilpivirine (RPV)</td>
      <td>NaN</td>
      <td>Depression</td>
      <td>AED’s, PPI’s, dexamethasone</td>
      <td>Must be taken w/ full meal; Don’t use if HIV RNA &gt;100k + CD4 &lt; 200; Don’t admin w/antacids</td>
    </tr>
    <tr>
      <td>Doravirine</td>
      <td>NaN</td>
      <td>Nightmares</td>
      <td>NaN</td>
      <td>NaN</td>
    </tr>
  </tbody>
</table>
       </table>
       <p style="text-align:justify">
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="background:white">
             <span style="font-family:Palatino">
              <span style="color:black">
               NNRTI Additional Information
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li style="list-style-type:none">
         <ul>
          <li style="list-style-type:none">
           <ul>
            <li style="list-style-type:none">
             <ul>
              <li style="list-style-type:none">
               <ul>
                <li style="list-style-type:none">
                </li>
               </ul>
              </li>
             </ul>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                Class-wide Side Effect: hepatitis, rashes
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                Resistance: K103N resistance to efavirenz and nevirapine
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
       </p>
       <p>
       </p>
       <table class="GridTable46" style="border-collapse:collapse; border:none" width="100%">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Protease inhibitors</td>
      <td>Hepatic Dose adj</td>
      <td>Specific SE</td>
      <td>Major DDI</td>
      <td>Special Points</td>
    </tr>
    <tr>
      <td>Atazanavir (ATV)</td>
      <td>Based on Childs Pugh</td>
      <td>Jaundice, Kidney stones AV block, Pancreatitis Rhabdomyolysis</td>
      <td>CYP3A4 Inhibitors PPI and H2 blockers</td>
      <td>Admin w/ meals</td>
    </tr>
    <tr>
      <td>Darunavir (DRV)</td>
      <td>NaN</td>
      <td>Rashes Pancreatitis</td>
      <td>CYP3A4 Inhibitors Azoles can be used cautiously with drug level monitoring</td>
      <td>Must d/c if rash</td>
    </tr>
    <tr>
      <td>Lopinavir (LPV)</td>
      <td>NaN</td>
      <td>AV block, QT changes Pancreatitis Hepatitis</td>
      <td>CYP3A4 Inhibitors</td>
      <td>Admin w/ meals</td>
    </tr>
  </tbody>
</table>
       </table>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="background:white">
             <span style="font-family:Palatino">
              <span style="color:black">
               Protease Inhibitor Additional Information
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li style="list-style-type:none">
         <ul>
          <li style="list-style-type:none">
           <ul>
            <li style="list-style-type:none">
             <ul style="list-style-type:circle">
              <li style="list-style-type:none">
               <ul>
                <li style="list-style-type:none">
                </li>
               </ul>
              </li>
             </ul>
            </li>
           </ul>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="background:white">
              <span style="font-family:Palatino">
               <span style="color:black">
                All protease inhibitors must be boosted:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Ritonavir: can cause MSK pain, rhabdomyolysis, not expected at usual doses
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Cobicistat: may increase Cr without effect on renal function
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:12.0pt">
          <span style="background:white">
           <span style="line-height:107%">
            <span style="font-family:Palatino">
             <span style="color:black">
              Class-wide Side Effects: hepatitis, hypersensitivity reactions,
             </span>
            </span>
           </span>
          </span>
         </span>
         <span style="font-size:12.0pt">
          <span style="background:white">
           <span style="line-height:107%">
            <span style='font-family:"Wingdings 3"'>
             <span style="color:black">
              #
             </span>
            </span>
           </span>
          </span>
         </span>
         <span style="font-size:12.0pt">
          <span style="background:white">
           <span style="line-height:107%">
            <span style="font-family:Palatino">
             <span style="color:black">
              cholesterol/TG, hyperglycemia, GI upset, lipodystrophy
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>